Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

le.

The Company's unaudited interim consolidated first quarter fiscal 2009 and 2008 financial statements are summarized below:

    Consolidated Statements of Operations
    for the three month period ended October 31
    (thousand $, except for per share data)

                                              2008         2007
    Revenue:
      Product revenue                           921          754
      License fees and royalties                198          131
      Research and development
       contracts                                  -            -
                                              1,119          885
    Expenses:
      Cost of sales                             447          313
      Research and development                1,641          782
      Operating, general and admin            1,310        1,313
      Amortization of intangibles                 3            7
      Amortization of capital assets             64           66
      Stock-based compensation                    -           12
      Interest income, net                     (205)        (104)
      Foreign exchange loss                     150          108
                                              3,410        2,497

    Loss before income taxes                 (2,291)      (1,612)

    Income taxes                                 30           32

    Loss for the period                      (2,321)      (1,644)

    Loss per share:                           (0.05)       (0.05)
      Basic and Diluted                       (0.05)       (0.05)



    Consolidated Statements of Cash Flows
    for the three month period ended October 31
    (thousand $)



                                               2008        2007

    Cash provided by (used in):
      Loss for the period                    (2,321)      (1,644)

    Items not involving cash:
      Amortization of capital assets   
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Research conducted ... Los Angeles, Boston University School of Medicine, Frederick National Laboratory for Cancer Research, ... world’s first multidisciplinary Open Access journal. , Christopher Ryan PhD, of Synedgen, ...
(Date:8/31/2015)... ... 31, 2015 , ... In recent years, biodegradable plastics have ... carbon footprints and compostability. These properties can help in limiting the degradation of ... of applications, the market for biodegradable plastics can be broadly segmented into packaging, ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Middle East & Africa Biomedical Sensors Market - ... offering. The Middle East ... at $0.84 billion by 2018 at a CAGR of ... future will bring Biomedical sensors that are adaptable to ...
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
Breaking Biology Technology:Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... 6, 2011 Van Andel Education Institute (VAEI) has ... to cooperatively recruit students interested in research training in ... genetic biology of human disease.    Under ... will work together to recruit qualified students at historically ...
...  Research Corporation for Science Advancement ( www.rescorp.org ), ... wholly to science, and the second-oldest overall (after ... its Honorary Centennial Observance Committee. The Committee, which ... 2012, is comprised of some of the most ...
... Inc. (Nasdaq: ECTE ), a company developing ... continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep ... from its clinical study of its Symphony tCGM System ... Data from the study confirm that Symphony successfully monitors ...
Cached Biology Technology:Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers 2Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 4
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... diverse potential applications include the development of ... coatings for medical implants, coatings for semiconductors, ... materials, microelectronics and responsive nanomaterials, and surface-sensitive ... The patented technology stems from the discovery ...
... have contended for millennia that burning incense is good ... is good for our brains too. In a new ... ), an international team of scientists, including researchers from ... describe how burning frankincense (resin from the Boswellia plant) ...
... First identified in 1899, y-larvae have been one of ... one has ever found an adult of these puzzling ... leading generations of marine zoologists to wonder just what ... in BioMed Centrals open access journal, BMC Biology, reports ...
Cached Biology News:Scripps Research Institute awarded patent for remarkable chemical technology 2Scripps Research Institute awarded patent for remarkable chemical technology 3Scripps Research Institute awarded patent for remarkable chemical technology 4Incense is psychoactive: Scientists identify the biology behind the ceremony 2Clue to mystery crustacean in parasite form 2
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
Biology Products: